Which has better valuation and earnings, WGS or HNGE?

GeneDx has higher earnings, but lower revenue than Hinge Health. GeneDx is trading at a lower price-to-earnings ratio than Hinge Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GeneDx $427.54M 5.10 -$21.02M -$3.64 N/A Hinge Health $720.06M 10.94 -$528.26M $1.28 76.25

Is WGS or HNGE more profitable?

Hinge Health has a net margin of 15.15% compared to GeneDx's net margin of -23.41%. Hinge Health's return on equity of 51.60% beat GeneDx's return on equity. Company Net Margins Return on Equity Return on Assets GeneDx -23.41% 4.12% 2.26% Hinge Health 15.15% 51.60% 14.16%

Does the media favor WGS or HNGE?

In the previous week, Hinge Health had 5 more articles in the media than GeneDx. MarketBeat recorded 9 mentions for Hinge Health and 4 mentions for GeneDx. GeneDx's average media sentiment score of 0.82 beat Hinge Health's score of 0.59 indicating that GeneDx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GeneDx 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hinge Health 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, HIMS or WGS?

Hims & Hers Health has higher revenue and earnings than GeneDx. Hims & Hers Health is trading at a lower price-to-earnings ratio than GeneDx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hims & Hers Health $2.35B 2.88 $128.37M -$0.63 N/A GeneDx $427.54M 5.10 -$21.02M -$3.64 N/A

Does the media favor HIMS or WGS?

In the previous week, Hims & Hers Health had 42 more articles in the media than GeneDx. MarketBeat recorded 46 mentions for Hims & Hers Health and 4 mentions for GeneDx. GeneDx's average media sentiment score of 0.82 beat Hims & Hers Health's score of 0.07 indicating that GeneDx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hims & Hers Health 4 Very Positive mention(s) 3 Positive mention(s) 36 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral GeneDx 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, WGS or CHE?

Chemed has higher revenue and earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GeneDx $427.54M 5.10 -$21.02M -$3.64 N/A Chemed $2.53B 2.63 $265.24M $19.91 25.55

Is WGS or CHE more profitable?

Chemed has a net margin of 10.60% compared to GeneDx's net margin of -23.41%. Chemed's return on equity of 31.77% beat GeneDx's return on equity. Company Net Margins Return on Equity Return on Assets GeneDx -23.41% 4.12% 2.26% Chemed 10.60% 31.77% 18.90%

Does the media prefer WGS or CHE?

In the previous week, Chemed had 7 more articles in the media than GeneDx. MarketBeat recorded 11 mentions for Chemed and 4 mentions for GeneDx. GeneDx's average media sentiment score of 0.82 beat Chemed's score of 0.13 indicating that GeneDx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GeneDx 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Chemed 2 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, WGS or RDNT?

RadNet has higher revenue and earnings than GeneDx. RadNet is trading at a lower price-to-earnings ratio than GeneDx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GeneDx $427.54M 5.10 -$21.02M -$3.64 N/A RadNet $2.04B 2.70 -$18.65M -$0.27 N/A

Is WGS or RDNT more profitable?

RadNet has a net margin of -0.93% compared to GeneDx's net margin of -23.41%. GeneDx's return on equity of 4.12% beat RadNet's return on equity. Company Net Margins Return on Equity Return on Assets GeneDx -23.41% 4.12% 2.26% RadNet -0.93% 2.61% 0.91%

Does the media refer more to WGS or RDNT?

In the previous week, RadNet had 1 more articles in the media than GeneDx. MarketBeat recorded 5 mentions for RadNet and 4 mentions for GeneDx. GeneDx's average media sentiment score of 0.82 beat RadNet's score of 0.51 indicating that GeneDx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GeneDx 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive RadNet 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, BLLN or WGS?

Billiontoone has higher earnings, but lower revenue than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than Billiontoone, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Billiontoone $305.11M 16.38 $7.45M $0.70 151.29 GeneDx $427.54M 5.10 -$21.02M -$3.64 N/A

Is BLLN or WGS more profitable?

Billiontoone has a net margin of 8.04% compared to GeneDx's net margin of -23.41%. Billiontoone's return on equity of 9.96% beat GeneDx's return on equity. Company Net Margins Return on Equity Return on Assets Billiontoone 8.04% 9.96% 5.35% GeneDx -23.41% 4.12% 2.26%

Does the media prefer BLLN or WGS?

In the previous week, Billiontoone had 11 more articles in the media than GeneDx. MarketBeat recorded 15 mentions for Billiontoone and 4 mentions for GeneDx. GeneDx's average media sentiment score of 0.82 beat Billiontoone's score of 0.08 indicating that GeneDx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Billiontoone 5 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GeneDx 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

GeneDx (WGS) Competitors

$73.09 +2.13 (+3.00%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$72.42 -0.67 (-0.91%)

As of 10/2/2026 07:55 PM Eastern

Compare

WGS vs. HNGE, HIMS, CHE, RDNT, and BLLN

Should you buy GeneDx stock or one of its competitors? GeneDx's main competitors and comparable companies include Hinge Health (HNGE), Hims & Hers Health (HIMS), Chemed (CHE), RadNet (RDNT), and Billiontoone (BLLN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does GeneDx compare to Hinge Health?

GeneDx (NASDAQ:WGS) and Hinge Health (NYSE:HNGE) are both mid-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

61.7% of GeneDx shares are owned by institutional investors. 25.2% of GeneDx shares are owned by insiders. Comparatively, 18.9% of Hinge Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Hinge Health had 5 more articles in the media than GeneDx. MarketBeat recorded 9 mentions for Hinge Health and 4 mentions for GeneDx. GeneDx's average media sentiment score of 0.82 beat Hinge Health's score of 0.59 indicating that GeneDx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GeneDx	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hinge Health	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

GeneDx currently has a consensus target price of $90.86, indicating a potential upside of 24.31%. Hinge Health has a consensus target price of $105.33, indicating a potential upside of 7.92%. Given GeneDx's higher possible upside, equities research analysts clearly believe GeneDx is more favorable than Hinge Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeneDx	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Hinge Health	0 Sell rating(s)	3 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.89

Hinge Health has a net margin of 15.15% compared to GeneDx's net margin of -23.41%. Hinge Health's return on equity of 51.60% beat GeneDx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeneDx	-23.41%	4.12%	2.26%
Hinge Health	15.15%	51.60%	14.16%

GeneDx has higher earnings, but lower revenue than Hinge Health. GeneDx is trading at a lower price-to-earnings ratio than Hinge Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeneDx	$427.54M	5.10	-$21.02M	-$3.64	N/A
Hinge Health	$720.06M	10.94	-$528.26M	$1.28	76.25

GeneDx has a beta of 1.95, meaning that its share price is 95% more volatile than the broader market. Comparatively, Hinge Health has a beta of 1.37, meaning that its share price is 37% more volatile than the broader market.

Summary

Hinge Health beats GeneDx on 10 of the 16 factors compared between the two stocks.

How does GeneDx compare to Hims & Hers Health?

Hims & Hers Health (NYSE:HIMS) and GeneDx (NASDAQ:WGS) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

Hims & Hers Health presently has a consensus price target of $32.43, indicating a potential upside of 11.98%. GeneDx has a consensus price target of $90.86, indicating a potential upside of 24.31%. Given GeneDx's stronger consensus rating and higher possible upside, analysts clearly believe GeneDx is more favorable than Hims & Hers Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hims & Hers Health	1 Sell rating(s)	12 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
GeneDx	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

In the previous week, Hims & Hers Health had 42 more articles in the media than GeneDx. MarketBeat recorded 46 mentions for Hims & Hers Health and 4 mentions for GeneDx. GeneDx's average media sentiment score of 0.82 beat Hims & Hers Health's score of 0.07 indicating that GeneDx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hims & Hers Health	4 Very Positive mention(s)	3 Positive mention(s)	36 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
GeneDx	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Hims & Hers Health has a beta of 2.44, indicating that its share price is 144% more volatile than the broader market. Comparatively, GeneDx has a beta of 1.95, indicating that its share price is 95% more volatile than the broader market.

Hims & Hers Health has a net margin of -5.51% compared to GeneDx's net margin of -23.41%. GeneDx's return on equity of 4.12% beat Hims & Hers Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hims & Hers Health	-5.51%	-6.51%	-1.20%
GeneDx	-23.41%	4.12%	2.26%

63.5% of Hims & Hers Health shares are held by institutional investors. Comparatively, 61.7% of GeneDx shares are held by institutional investors. 11.8% of Hims & Hers Health shares are held by insiders. Comparatively, 25.2% of GeneDx shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Hims & Hers Health has higher revenue and earnings than GeneDx. Hims & Hers Health is trading at a lower price-to-earnings ratio than GeneDx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hims & Hers Health	$2.35B	2.88	$128.37M	-$0.63	N/A
GeneDx	$427.54M	5.10	-$21.02M	-$3.64	N/A

Summary

GeneDx beats Hims & Hers Health on 10 of the 17 factors compared between the two stocks.

How does GeneDx compare to Chemed?

GeneDx (NASDAQ:WGS) and Chemed (NYSE:CHE) are both mid-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, dividends, risk and analyst recommendations.

In the previous week, Chemed had 7 more articles in the media than GeneDx. MarketBeat recorded 11 mentions for Chemed and 4 mentions for GeneDx. GeneDx's average media sentiment score of 0.82 beat Chemed's score of 0.13 indicating that GeneDx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GeneDx	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Chemed	2 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Chemed has a net margin of 10.60% compared to GeneDx's net margin of -23.41%. Chemed's return on equity of 31.77% beat GeneDx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeneDx	-23.41%	4.12%	2.26%
Chemed	10.60%	31.77%	18.90%

GeneDx currently has a consensus price target of $90.86, indicating a potential upside of 24.31%. Chemed has a consensus price target of $554.60, indicating a potential upside of 9.03%. Given GeneDx's stronger consensus rating and higher possible upside, analysts plainly believe GeneDx is more favorable than Chemed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeneDx	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Chemed	0 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.29

61.7% of GeneDx shares are held by institutional investors. Comparatively, 95.9% of Chemed shares are held by institutional investors. 25.2% of GeneDx shares are held by company insiders. Comparatively, 3.3% of Chemed shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Chemed has higher revenue and earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeneDx	$427.54M	5.10	-$21.02M	-$3.64	N/A
Chemed	$2.53B	2.63	$265.24M	$19.91	25.55

GeneDx has a beta of 1.95, meaning that its share price is 95% more volatile than the broader market. Comparatively, Chemed has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market.

Summary

Chemed beats GeneDx on 9 of the 17 factors compared between the two stocks.

How does GeneDx compare to RadNet?

GeneDx (NASDAQ:WGS) and RadNet (NASDAQ:RDNT) are both mid-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, media sentiment, dividends, profitability, valuation and risk.

61.7% of GeneDx shares are held by institutional investors. Comparatively, 77.9% of RadNet shares are held by institutional investors. 25.2% of GeneDx shares are held by insiders. Comparatively, 5.1% of RadNet shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

RadNet has higher revenue and earnings than GeneDx. RadNet is trading at a lower price-to-earnings ratio than GeneDx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeneDx	$427.54M	5.10	-$21.02M	-$3.64	N/A
RadNet	$2.04B	2.70	-$18.65M	-$0.27	N/A

GeneDx currently has a consensus target price of $90.86, indicating a potential upside of 24.31%. RadNet has a consensus target price of $90.00, indicating a potential upside of 28.70%. Given RadNet's higher possible upside, analysts plainly believe RadNet is more favorable than GeneDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeneDx	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
RadNet	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

RadNet has a net margin of -0.93% compared to GeneDx's net margin of -23.41%. GeneDx's return on equity of 4.12% beat RadNet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeneDx	-23.41%	4.12%	2.26%
RadNet	-0.93%	2.61%	0.91%

GeneDx has a beta of 1.95, suggesting that its stock price is 95% more volatile than the broader market. Comparatively, RadNet has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market.

In the previous week, RadNet had 1 more articles in the media than GeneDx. MarketBeat recorded 5 mentions for RadNet and 4 mentions for GeneDx. GeneDx's average media sentiment score of 0.82 beat RadNet's score of 0.51 indicating that GeneDx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GeneDx	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
RadNet	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

GeneDx and RadNet tied by winning 8 of the 16 factors compared between the two stocks.

How does GeneDx compare to Billiontoone?

Billiontoone (NASDAQ:BLLN) and GeneDx (NASDAQ:WGS) are both mid-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

Billiontoone has a net margin of 8.04% compared to GeneDx's net margin of -23.41%. Billiontoone's return on equity of 9.96% beat GeneDx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Billiontoone	8.04%	9.96%	5.35%
GeneDx	-23.41%	4.12%	2.26%

In the previous week, Billiontoone had 11 more articles in the media than GeneDx. MarketBeat recorded 15 mentions for Billiontoone and 4 mentions for GeneDx. GeneDx's average media sentiment score of 0.82 beat Billiontoone's score of 0.08 indicating that GeneDx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Billiontoone	5 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GeneDx	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Billiontoone has higher earnings, but lower revenue than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than Billiontoone, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Billiontoone	$305.11M	16.38	$7.45M	$0.70	151.29
GeneDx	$427.54M	5.10	-$21.02M	-$3.64	N/A

Billiontoone presently has a consensus target price of $126.25, suggesting a potential upside of 19.22%. GeneDx has a consensus target price of $90.86, suggesting a potential upside of 24.31%. Given GeneDx's stronger consensus rating and higher probable upside, analysts clearly believe GeneDx is more favorable than Billiontoone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Billiontoone	2 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.45
GeneDx	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

61.7% of GeneDx shares are held by institutional investors. 50.2% of Billiontoone shares are held by company insiders. Comparatively, 25.2% of GeneDx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Billiontoone beats GeneDx on 9 of the 15 factors compared between the two stocks.

Get GeneDx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

WGS vs. The Competition

Export

Metric	GeneDx	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.12B	$9.57B	$7.14B	$13.18B
Dividend Yield	N/A	2.61%	2.53%	16.77%
P/E Ratio	-20.08	34.21	274.83	26.04
Price / Sales	5.10	4.73	616.61	84.99
Price / Cash	30.96	120.59	77.60	51.75
Price / Book	6.93	5.15	10.93	6.31
Net Income	-$21.02M	$315.68M	$3.51B	$362.16M
7 Day Performance	-17.32%	-2.59%	-2.00%	-1.66%
1 Month Performance	-16.36%	-3.19%	-6.15%	-4.50%
1 Year Performance	-38.20%	7.93%	7.45%	2.06%

GeneDx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
WGS GeneDx	3.3919 of 5 stars	$73.09 +3.0%	$90.86 +24.3%	-37.7%	$2.12B	$427.54M	N/A	1,300	News Coverage Analyst Forecast
HNGE Hinge Health	3.7413 of 5 stars	$97.28 +0.0%	$105.33 +8.3%	+85.1%	$7.83B	$587.86M	75.80	1,437	Analyst Forecast
HIMS Hims & Hers Health	2.2038 of 5 stars	$29.59 -0.7%	$32.43 +9.6%	-50.0%	$6.93B	$2.35B	N/A	2,442	Trending News Insider Trade Gap Up
CHE Chemed	3.4601 of 5 stars	$506.66 +0.3%	$554.60 +9.5%	+15.2%	$6.63B	$2.53B	25.49	15,811	Insider Trade
RDNT RadNet	3.5573 of 5 stars	$68.93 0.0%	$90.00 +30.6%	-10.7%	$5.48B	$2.04B	N/A	11,264	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:WGS) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GeneDx (WGS) Competitors